Genor Biopharma (Stock code: 6998.HK) announced today that the company has obtained the IND approval from the National Medical Products Administration (NMPA) on June 2, 2022 for the phase I/II clinical trials of GB263T, a novel EGFR/cMET/cMET trispecific therapeutic antibody.

Genor Biopharma (Stock code: 6998.HK) announced today that the company has obtained the IND approval from the National Medical Products Administration (NMPA) for the phase I/II clinical trials of GB261, a CD20/CD3 bispecific antibody.

Genor Biopharma (Stock code: 6998.HK) announced today that the first patient has been successfully dosed in a first-in-human (FIH) clinical trial of GB263T, a novel EGFR/cMET/cMET trispecific therapeutic antibody.

Up to now, Genor Biopharma has achieved the successful approval of GB242 (infliximab) was realized and the product will be commercialized with more NDA applications on the way. Successfully optimized its product pipeline and accelerated key clinical trials; established a global first-in-class/differentiated research and development platform for early identification of bi-specific/multi-specific antibodies in immune-oncology; started its journey of FIC/BIC R&D; and vigorously promoted global innovation and business development.

The company has obtained the EC approval from the Bellberry HREC Ethics Committee in Australia, for the first-in-human (FIH) clinical trial of GB263T, a novel EGFR/cMET/cMET trispecific therapeutic antibody, in patients with advanced Non-Small Cell Lung Cancer (NSCLC) and other solid tumors.